RXRX.US Recursion Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
2.72 USD
Close of Nov 18, 2026
2.50 5.24
Market cap
USD 1.70B
P/E
-
P/B
2.00x
ROE
-54.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RXRX.US undervalued?

Graham number

The Graham number of Recursion Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Recursion Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Recursion Pharmaceuticals Inc yet.

Recursion Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced…

Full company profile